PT  - JOURNAL ARTICLE
AU  - Stolicyn, Aleks
AU  - Harris, Mathew A.
AU  - de Nooij, Laura
AU  - Shen, Xueyi
AU  - Macfarlane, Jennifer A.
AU  - Campbell, Archie
AU  - McNeil, Christopher J.
AU  - Sandu, Anca-Larisa
AU  - Murray, Alison D.
AU  - Waiter, Gordon D.
AU  - Lawrie, Stephen M.
AU  - Steele, Douglas J.
AU  - McIntosh, Andrew M.
AU  - Romaniuk, Liana
AU  - Whalley, Heather C.
TI  - Disrupted Limbic-Prefrontal Effective Connectivity in Response to Fearful Faces in Lifetime Depression
AID  - 10.1101/2023.07.18.23292846
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.18.23292846
4099  - http://medrxiv.org/content/early/2023/12/08/2023.07.18.23292846.short
4100  - http://medrxiv.org/content/early/2023/12/08/2023.07.18.23292846.full
AB  - Background Multiple brain imaging studies of negative emotional bias in major depressive disorder (MDD) have used images of fearful facial expressions and focused on the amygdala and the prefrontal cortex. The results have, however, been inconsistent, potentially due to small sample sizes (typically N < 50). It remains unclear if any alterations are a characteristic of current depression or of past experience of depression, and whether there are MDD-related changes in effective connectivity between the two brain regions.Methods Activations and effective connectivity between the amygdala and dorsolateral prefrontal cortex (DLPFC) in response to fearful face stimuli were studied in a large population-based sample from Generation Scotland. Participants either had no history of MDD (N = 664 in activation analyses, N = 474 in connectivity analyses) or had a diagnosis of MDD during their lifetime (LMDD, N = 290 in activation analyses, N = 214 in connectivity analyses). The within-scanner task involved implicit facial emotion processing of neutral and fearful faces.Results Compared to controls, LMDD was associated with increased activations in left amygdala (PFWE = 0.031 , k E = 4) and left DLPFC (PFWE = 0.002 , k E = 33), increased mean bilateral amygdala activation (β = 0.0715 , P = 0.0314), and increased inhibition from left amygdala to left DLPFC, all in response to fearful faces contrasted to baseline. Results did not appear to be attributable to depressive illness severity or antidepressant medication status at scan time.Limitations Most studied participants had past rather than current depression, average severity of ongoing depression symptoms was low, and a substantial proportion of participants were receiving medication. The study was not longitudinal and the participants were only assessed a single time.Conclusions LMDD is associated with hyperactivity of the amygdala and DLPFC, and with stronger amygdala to DLPFC inhibitory connectivity, all in response to fearful faces, unrelated to depression severity at scan time. These results help reduce inconsistency in past literature and suggest disruption of ‘bottom-up’ limbic-prefrontal effective connectivity in depression.Competing Interest StatementJDS previously received research funding from Wyeth and Indivior. AMM previously received research grant support from Pfizer, Eli Lilly and Janssen, as well as speaker fees from Illumina. HCW previously received research grant support from Pfizer. None of these funding sources are connected to the present study. No potential conflicts of interest are reported for other authors.Funding StatementThis study was supported and funded by the Wellcome Trust Strategic Award "Stratifying Resilience and Depression Longitudinally" (STRADL) (Reference 104036/Z/14/Z), and the Medical Research Council Mental Health Pathfinder Award "Leveraging routinely collected and linked research data to study the causes and consequences of common mental disorders" (Reference MRC-MC_PC_17209). The work was also supported through the Lister Institute of Preventive Medicine award with reference 173096 and the Wellcome-University of Edinburgh Institutional Strategic Support Fund (Reference 204804/Z/16/Z). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (Reference CZD/16/6) and the Scottish Funding Council (Reference HR03006), and is currently supported by the Wellcome Trust (Reference 216767/Z/19/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the NHS Tayside committee on research ethics (reference 14/SS/0039).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from the Generation Scotland dataset are available through application to the Generation Scotland Access Committee (access{at}generationscotland.org) and Edinburgh DataVault (https://doi.org/10.7488/8f68f1ae-0329-4b73-b189-c7288ea844d7).https://doi.org/10.7488/8f68f1ae-0329-4b73-b189-c7288ea844d7